These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12096228)

  • 1. Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus.
    Katsifis GE; Tzioufas AG; Vlachoyiannopoulos PG; Voulgarelis M; Moutsopoulos HM; Ioannidis JP
    Rheumatology (Oxford); 2002 Jul; 41(7):780-6. PubMed ID: 12096228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
    Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
    J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy.
    Chiu SJ; Ou LS; Tsai TL; Hung IJ; Huang JL
    Clin Rheumatol; 2006 Jul; 25(4):515-9. PubMed ID: 16283418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate and severe neutropenia in patients with systemic lupus erythematosus.
    Martínez-Baños D; Crispín JC; Lazo-Langner A; Sánchez-Guerrero J
    Rheumatology (Oxford); 2006 Aug; 45(8):994-8. PubMed ID: 16484291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study.
    Baba S; Katsumata Y; Kawaguchi Y; Gono T; Sugiura T; Kanno T; Hara M; Yamanaka H
    BMC Womens Health; 2011 Jun; 11():28. PubMed ID: 21663683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy.
    Opastirakul S; Chartapisak W
    Pediatr Nephrol; 2005 Dec; 20(12):1750-5. PubMed ID: 16133037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.
    Pryor BD; Bologna SG; Kahl LE
    Arthritis Rheum; 1996 Sep; 39(9):1475-82. PubMed ID: 8814058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
    Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
    Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus.
    Martinelli R; Pereira LJ; Santos ES; Rocha H
    Nephron; 1996; 74(2):313-7. PubMed ID: 8893147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
    Petri M; Jones RJ; Brodsky RA
    Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.
    Garnier C; Ribes D; Chauveau D; Huart A; Pugnet G; Adoue D; Prevot G; Alric L; Delobel P; Derumeaux H; Mengelle C; Sailler L; Moulis G
    J Rheumatol; 2018 Nov; 45(11):1541-1548. PubMed ID: 30008461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus.
    Borba EF; Ribeiro AC; Martin P; Costa LP; Guedes LK; Bonfá E
    J Clin Rheumatol; 2010 Apr; 16(3):119-22. PubMed ID: 20216330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.
    Martin-Suarez I; D'Cruz D; Mansoor M; Fernandes AP; Khamashta MA; Hughes GR
    Ann Rheum Dis; 1997 Aug; 56(8):481-7. PubMed ID: 9306871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus.
    Boumpas DT; Barez S; Klippel JH; Balow JE
    Ann Intern Med; 1990 May; 112(9):674-7. PubMed ID: 2334081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.
    McDermott EM; Powell RJ
    Ann Rheum Dis; 1996 Apr; 55(4):224-9. PubMed ID: 8733438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
    Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
    Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Zhong S; Huang M; Yang X; Liang L; Wang Y; Romkes M; Duan W; Chan E; Zhou SF
    Br J Clin Pharmacol; 2006 Oct; 62(4):457-72. PubMed ID: 16995867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
    J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.
    Katsifis GE; Tzioufas AG
    Lupus; 2004; 13(9):673-8. PubMed ID: 15485101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement.
    Morton M; Edmonds S; Doherty AM; Dhaygude A; Helbert M; Venning M
    Rheumatol Int; 2012 Nov; 32(11):3373-82. PubMed ID: 22045517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.